BEIJING, Sept. 3 (Xinhua) -- China's tech giant Huawei and China National Biotec Group (CNBG), the biological product arm of China National Pharmaceutical Group Co., Ltd. (Sinopharm), signed a strategic cooperation agreement on COVID-19 vaccines' resource guarantee and service support on Wednesday.
Under the agreement, the two sides will also carry out in-depth cooperation in the fields of disease prevention and biotechnology application innovation.
According to the agreement, the CNBG will focus on the development of biotechnology products such as coronavirus vaccines and provide resource guarantee and service support for Huawei in a bid to protect the life safety and health of Huawei's 200,000 employees.
Liu Jingzhen, chairman of Sinopharm, noted that this collaboration is not only the actual demand for battling against the coronavirus pandemic, but also the development needs of complementary advantages.
According to Liu, the two sides will realize a mutually beneficial and win-win situation in the area of disease prevention and digital transformation in the future.
(Edited by Yang Yifan with Xinhua Silk Road, yangyifan@xinhua.org)
A single purchase
